MedPath

Transcranial direct current stimulation in the treatment of juvenile depression in a naturalistic inpatient setting: A double-blind randomized controlled feasibility trial

Not Applicable
Recruiting
Conditions
Severe depressive episode without psychotic symptoms
F32.2
F32.1
F32.3
Moderate depressive episode
Severe depressive episode with psychotic symptoms
Registration Number
DRKS00027066
Lead Sponsor
Kinder- und JugendpsychiatrieEvangelisches Klinikum Bethel gGmbH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

Written informed consent (parents)
Written informed assent (participants)
Age: 13-17;11 years at randomization
Clinical diagnosis of depressive episode (ICD 10: F32.1, 32.2, 32.3, BDI-II >15)
Both gender
IQ > 80

Exclusion Criteria

Suicidality (clinical assessment)
Bipolar disorder
Schizophrenia
Epilepsy/ epileptic seizure(s) in the past
Family history of epileptic seizures
Pregnancy or lactation
Non-German-speaking youth or caregiver
Low compliance (clinical assessment)
Diagnosis of pervasive developmental and neurological disorder
Participation in another clinical trial during the whole study period
Past or present neurological disease or head surgery
Born before the 37th week of pregnancy
Birth weight < 2500 g
Acute dermatological disease of scalp
Substance abuse

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary objective is to assess whether tDCS (transcraniell direct current stimulation) reduces patient reported severity of depressive symptoms compared with sham stimulation. We expect that the primary outcome Beck's Depression Inventory Revision (BDI-II) score between T1 (baseline) and T3 (4th week after the start of stimulation) will decrease.
Secondary Outcome Measures
NameTimeMethod
The second objective is to assess feasibility, acceptability and adherence towards tDCS.
© Copyright 2025. All Rights Reserved by MedPath